CEO Executive AssistantAn initial public offering is among the most time-intensive events a pharmaceutical or biotech executive will manage in a company’s lifecycle. The IPO process demands extraordinary CEO and CFO time investment across prospectus preparation, regulatory review management, investor education, and roadshow execution, all while the company continues to operate and the pipeline continues to require oversight. Managing this process without allowing it to consume the entire leadership team requires deliberate calendar architecture.
This article provides a practical framework for pharmaceutical and biotech executives navigating the IPO calendar challenge.
The Time Demands of a Pharma IPO
A pharmaceutical or biotech IPO typically unfolds over six to twelve months from the decision to proceed through the first day of trading. The timeline includes several distinct phases, each with different time demands:
Pre-filing preparation (three to six months before filing). This phase involves prospectus drafting with investment banking, legal, and financial teams, financial audit preparation and review, SEC comment preparation, and investor targeting strategy development. The CEO and CFO are the primary executives involved, with the CMO engaged for clinical pipeline sections of the prospectus.
SEC review and comment period (two to four months). After S-1 filing, the SEC typically issues comments requiring response. This period involves intensive work between the company, legal counsel, and investment banking to address regulatory comments while maintaining accuracy and completeness.
Roadshow preparation and execution (two to three weeks before pricing). The roadshow is the most intensive period: presenting the company story to institutional investors in concentrated, back-to-back meetings across multiple cities, often covering 50 to 100 investor meetings in ten to fifteen days.
Post-IPO stabilization (first three to six months as a public company). Adapting to public company reporting requirements, managing new investor relationships, and maintaining quarterly earnings cadences while sustaining the underlying business.
Each phase has different time demands and requires different calendar strategies.
Pre-Filing Calendar Management
The pre-filing phase is often underestimated in its time demands. Prospectus preparation is intensive: the CEO, CFO, and General Counsel will invest significant hours reviewing and refining prospectus language. The CMO will be deeply involved in clinical pipeline descriptions. This work is essential to the quality of the final document, but it creates a risk of crowding out routine business operations.
Managing this phase effectively requires:
Creating dedicated IPO preparation blocks. Reserve two to four hours per day, consistently, for prospectus-related work rather than trying to squeeze it into available gaps. This predictability allows investment banking and legal teams to schedule their work around known CEO availability.
Maintaining the business operational cadence. The pipeline does not pause during IPO preparation. Existing quarterly and monthly review cadences should be maintained, with team leads empowered to make operational decisions without escalating to the CEO during preparation periods.
Limiting the IPO preparation team. Involve only those executives whose participation is essential at each stage. The full senior team does not need to be in every prospectus review session. Limiting participation reduces collective time cost and produces better-focused discussions.
A pharma CEO time audit conducted during IPO preparation typically reveals that executives who create dedicated preparation blocks achieve better prospectus quality in fewer total hours than those who work reactively around other demands.
Managing the Roadshow Window
The roadshow is the most calendar-intensive period of the entire IPO process. A typical biotech IPO roadshow involves one hundred percent CEO and CFO time for ten to fifteen consecutive business days, with investor presentations from early morning through early evening in multiple cities.
Several practices help executives manage this extreme period:
Pre-roadshow preparation investment. The most effective roadshows are built on intensive preparation: a week of structured rehearsal covering Q&A scenarios, financial model questions, clinical pipeline objections, and competitive positioning. CEOs who invest in this preparation are less cognitively fatigued during the roadshow itself because they are drawing on pre-analyzed frameworks rather than reasoning in real time under pressure.
Physical and cognitive management. Roadshows involve long hours, time zone changes, and constant performance demands. Protecting eight hours of sleep per night is not a luxury; it is a performance requirement. Scheduling meals, exercise, and recovery time into the roadshow calendar, not just investor meetings, sustains performance through the full duration.
Chief of staff support. During the roadshow, the chief of staff or a senior associate should manage all logistics and non-essential communications, shielding the CEO and CFO from anything that does not require their immediate attention. The roadshow is the one period where nearly all email, call, and meeting management can legitimately be delegated.
Business continuity planning. Before entering the roadshow, ensure that the CMO or another designated executive has full operational authority to manage any clinical or operational developments that arise during the two-week window. Most urgent-seeming events can wait for the CEO’s return; genuine crises have an escalation path.
Protecting Pipeline Continuity During IPO
The pipeline is the central value driver for most biotech IPOs, and the company cannot afford for it to be neglected during the IPO process. Yet the time demands of prospectus preparation and roadshow execution create real risk of pipeline oversight gaps.
Managing this risk requires deliberate delegation. The CMO must have full operational authority during the IPO period for clinical pipeline management. Data safety monitoring board decisions, protocol amendments, and enrollment management should all flow through the CMO without requiring CEO involvement, except for developments that are material and require prospectus updates or investor disclosure.
Before the roadshow, conduct a review of all expected clinical events during the IPO window. If any major data readouts, regulatory decisions, or trial milestone events are expected, ensure they are either resolved before the roadshow or that there is a clear plan for how they will be communicated in the context of a public offering.
Board Management During the IPO Process
The board plays an active role in the IPO process, with fiduciary responsibilities around prospectus accuracy and pricing decisions. This creates additional CEO time demands for board communication and alignment.
Effective board management during IPO requires:
- A dedicated IPO committee of the board, typically including the lead independent director and one or two other members, to manage the ongoing IPO oversight process without requiring full board involvement in every detail
- Monthly updates to the full board on IPO progress, with between-meeting communications managed through the IPO committee
- A clear escalation protocol for board-level decisions that may arise during the roadshow (such as pricing negotiations)
The IPO committee structure prevents the full board from becoming a continuous presence in the CEO’s schedule during the IPO preparation period.
Investor Relations After IPO: The New Calendar Reality
The IPO creates a permanent change in the CEO’s calendar obligations. As a public company, quarterly earnings calls, SEC filings, and ongoing investor communication become standing obligations that did not exist before.
Preparing for this new reality before the IPO, rather than adapting to it afterward, significantly reduces the time management disruption of becoming public:
- Establish the quarterly earnings preparation cadence during the post-IPO stabilization period
- Build investor relations infrastructure (dedicated IR professional, IR website, analyst coverage management) before the company goes public if possible
- Develop investor communication templates and frameworks during the IPO process that can be adapted for ongoing quarterly use
According to Harvard Business Review’s research on CEO time management, executives who establish structured communication cadences at major transition points adapt more effectively than those who improvise their approach after the transition.
The biopharma M&A time Parallel
The time management challenges of an IPO share significant parallels with those of an M&A transaction. Both involve intensive periods of external engagement, legal and financial process management, and business continuity challenges. Executives who have managed major M&A transactions will find many of the same disciplines applicable to the IPO process.
In both contexts, the core challenge is maintaining a functional leadership presence for the ongoing business while devoting significant personal bandwidth to the transaction. In both cases, the answer lies in strong delegation, structured information flow, and a clear boundary between what the CEO must personally manage and what can be handled by empowered direct reports.
Post-IPO Calendar Adjustment
The six months following an IPO are often the most difficult for newly public company CEOs. The company is now subject to public market scrutiny, analyst coverage, and quarterly earnings expectations, while simultaneously trying to execute its pre-IPO strategic plan. The calendar demands of being a public company were not present during the pre-IPO period.
Managing this adjustment requires:
- Explicitly blocking time for the new public company obligations (earnings preparation, analyst relations, investor meetings) in the calendar structure
- Assessing which pre-IPO calendar commitments can be reduced now that additional resources are available
- Protecting strategic and pipeline oversight time from being crowded out by investor relations obligations
The executives who navigate this adjustment most successfully are those who treat the post-IPO calendar as a design challenge, building a new operating rhythm for the public company context rather than simply adding public company obligations to an already full private company calendar.
Conclusion
Managing the calendar during a pharmaceutical or biotech IPO requires treating the IPO as a defined operational mode with structured phases, each demanding different time allocation strategies. The executives who succeed are those who invest heavily in preparation, build strong operational delegation for the business, manage the roadshow as a performance event requiring deliberate management, and design their post-IPO calendar to accommodate their new public company obligations without sacrificing strategic effectiveness.
The IPO is one of the defining events in a pharmaceutical company’s history. The quality of executive leadership during the process sets the company’s culture and investor relationships for years to come. Managing it well begins with managing time well.
Related Reading
For further context, explore Calendar Management for Commercial Real Estate Executives and Calendar Management for Construction CEO Bid Deadlines Schedule.